Founded Year



Acquired | Acquired

Total Raised


About MacuLogix

MacuLogix develops eye care medical technologies and pharmaceuticals products. The company offers screening tools for the early diagnosis of age-related macular degeneration. MacuLogix was formerly known as Apeliotus Vision Science, Inc. The company was founded in 2008 and is based in Middletown, Pennsylvania. On July 26th, 2022, MacuLogix was acquired by LumiThera. The terms of the transaction were not disclosed.

MacuLogix Headquarters Location

1000 Kreider Drive Suite 700

Middletown, Pennsylvania, 17057,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

MacuLogix's Products & Differentiation

See MacuLogix's products and how their products differentiate from alternatives and competitors

  • AdaptDx Pro

    The AdaptDx Pro is a head-mounted, mobile dark adaptometer powered by artificial intelligence named Theia. Theia runs the test from start to finish using adaptive coaching for a more reliable results and a consistent experience. The Rod Intercept time as measured by AdaptDx Pro gives eye care professionals a functional measurement of retinal health to help detect and monitor age-related macular degeneration.


    Unlike other ophthalmic testing devices, AdaptDx Pro is completely mobile, allowing the test to be taken anywhere in any lighting conditions. Theia runs the test so that the human technician can foc… 

Expert Collections containing MacuLogix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MacuLogix is included in 4 Expert Collections, including Medical Devices.


Medical Devices

8,452 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health Monitoring & Diagnostics

313 items

Companies developing technology for computer-aided diagnostic imaging. Companies tagged as #ComputerAidedDxImaging


Health IT

8,260 items

MacuLogix Patents

MacuLogix has filed 18 patents.

The 3 most popular patent topics include:

  • GPS navigation devices
  • Inflammations
  • Medical tests
patents chart

Application Date

Grant Date


Related Topics




Vision, Visual system, Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology


Application Date


Grant Date



Related Topics

Vision, Visual system, Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology



Latest MacuLogix News

LumiThera acquires AdaptDx Pro from MacuLogix

Aug 4, 2022

Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio LumiThera has purchased the assets of MacuLogix through its wholly owned subsidiary, according to a press release. MacuLogix developed the AdaptDx Pro dark adaptometer, a wearable device used to diagnose dry age-related macular degeneration. It launched in 2020. “AdaptDx Pro can identify dry AMD patients at the earliest timepoint, in advance of pathology and before vision loss,” Clark E. Tedford, PhD, president and CEO of LumiThera, said in the release. “The AdaptDx wearable, light-based early diagnostic for dry AMD adds a complementary assessment of retinal health to the LumiThera product line, further expanding LumiThera’s synergistic platform of products for eye care professionals. We are excited to combine diagnosis, treatment and monitoring platforms to provide a complete solution for dry AMD patients.” The AdaptDx device measures the inability to adapt to low light levels, an early sign of AMD. More than 1 million tests have been performed and 200,000 patients have been diagnosed with the device, according to Greg Jackson, PhD, former MacuLogix chief technology officer and co-founder. Terms of the deal were not announced. Read more about

MacuLogix Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MacuLogix Rank

  • When was MacuLogix founded?

    MacuLogix was founded in 2008.

  • Where is MacuLogix's headquarters?

    MacuLogix's headquarters is located at 1000 Kreider Drive, Middletown.

  • What is MacuLogix's latest funding round?

    MacuLogix's latest funding round is Acquired.

  • How much did MacuLogix raise?

    MacuLogix raised a total of $123.4M.

  • Who are the investors of MacuLogix?

    Investors of MacuLogix include LumiThera, Paycheck Protection Program, Fisk Ventures, Roche Venture Fund, Vivo Capital and 8 more.

  • What products does MacuLogix offer?

    MacuLogix's products include AdaptDx Pro.

  • Who are MacuLogix's customers?

    Customers of MacuLogix include Individual Optometry Practices.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.